IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ImageneBio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$4.00−0.04 (-0.99%)

Close on Oct 19, 2026

Market cap: $64.65M
P/E (TTM): –
Dividend yield: –

ImageneBio, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	0.40	1.10	–	–	–	–
Stock-Based Compensation	15	0	7.63	7.53	5.18	1.80
Deferred Income Taxes	0	0	–	–	–	–
Change in Accounts Payable	-2.82	-0.52	-2.87	-0.29	0.36	0.52
Change in Unearned Revenue	-0.65	0.51	-9.16	-16	-31	-9.19
Operating Cash Flow	-48	-21	-80	-74	-60	-38
Capital Expenditures	–	–	-0.41	-1.43	-1.76	-0.77
Sale of Property, Plant & Equipment	0	0.97	–	–	–	–
Purchase of Investments	-10	0	-90	-216	–	–
Sale & Maturity of Investments	9.80	10	155	118	–	–
Investing Cash Flow	-5.81	11	64	-99	-1.76	2.92
Share Repurchases	–	–	-0.66	–	–	–
Stock Issued	–	–	37	–	–	–
Debt Issued	15	7.50	–	–	–	–
Financing Cash Flow	135	6.91	76	1.10	132	116
Foreign Exchange Rate Adjustments	0.60	0.09	–	–	–	–
Net Change in Cash	82	-3.20	–	–	–	–
Free Cash Flow	–	–	-80	-76	-62	-39
Income Taxes Paid	0.02	0.22	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -7370.1%
Net margin: -6560.5%
Return on equity, FY2025: 330.7%

Financial strength

Current ratio: 21.47
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1440.4%

Valuation

P/E ratio: –
Price to sales: 80.81
Price to book: 0.46
Dividend yield: –